{"id":"W4310779922","doi":"10.1038/s41591-022-02041-5","title":"Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; McGill University Health Centre","funders":"Roche Diagnostics; Amgen Canada; Pfizer Japan; Novartis Pharma; Esperion Therapeutics; HLS Therapeutics; Daiichi Sankyo Europe; Servier; Teijin Pharma; Otsuka Pharmaceutical; Cytokinetics; Astellas Pharma; Deutsche Forschungsgemeinschaft; Astellas Foundation for Research on Metabolic Disorders; Boehringer Ingelheim Japan; ReCor Medical; Mitsubishi Tanabe Pharma Corporation; Medicines Company; MSD K.K.; AstraZeneca Canada; Siemens Medical Solutions USA; AstraZeneca; Amarin Corporation; Defense Acquisition Program Administration; Boston Scientific Corporation; Regeneron Pharmaceuticals; Intercept Pharmaceuticals; Bayer HealthCare; Omron Healthcare; Kowa Company; Sanofi; Amgen; Anthera; Vifor Pharma; Actelion Pharmaceuticals; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Empagliflozin; Ejection fraction; Hazard ratio; Medicine; Heart failure; Internal medicine; Cardiology; Placebo; Clinical endpoint; Confidence interval; Randomized controlled trial; Diabetes mellitus; Type 2 diabetes; Endocrinology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004964893,0.000227028,0.0009778553,0.001153801,0.00006226741,0.00000403891,0.0001775202,0.0001481254,0.001756866],"category_scores_gemma":[0.0002477945,0.0001682501,0.0001913655,0.003121043,0.0001073408,0.00009446123,0.0001049405,0.0006972242,0.000001319531],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002227503,"about_ca_system_score_gemma":0.00005412869,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004289173,"about_ca_topic_score_gemma":0.0007558384,"domain_scores_codex":[0.9976663,0.0001518214,0.000490872,0.0004139922,0.001024374,0.0002526211],"domain_scores_gemma":[0.9985285,0.000293087,0.000256947,0.0006532964,0.0001669225,0.0001012016],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06076367,0.00400855,0.8593432,0.0007808637,0.01369294,0.0001534463,0.002140142,0.002499683,0.01443345,0.0002273554,0.04021041,0.001746289],"study_design_scores_gemma":[0.02418851,0.003691205,0.9312982,0.0002141011,0.005479835,0.000001897002,0.001879836,0.000473811,0.002937709,0.000008547271,0.02966075,0.0001655821],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909157,0.001538892,0.00001704321,0.004487435,0.0002859232,0.001031506,0.00001844778,0.00004920741,0.001655872],"genre_scores_gemma":[0.9980001,0.00004345718,0.0004167757,0.0001675662,0.0001398915,0.0001233793,0.0003828433,0.00002441998,0.0007015258],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07195501,"threshold_uncertainty_score":0.9991556,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01971254737780448,"score_gpt":0.2940950505511354,"score_spread":0.2743825031733309,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}